Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 18 Myeloproliferative Disorders 4 Glioma 4 Myelodysplastic Syndromes 3 Cholangiocarcinoma 3 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Leukemia 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Ependymoma 2 Chondrosarcoma 2 Biliary Tract Neoplasms 2 Xanthogranuloma, Juvenile 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasms, Unknown Primary 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 IDH1-Mutated Malignancies 1 IDH1 Mutation Myeloid Neoplasms 1 Histiocytic Sarcoma 1

Interventions

ivosidenib 1 Magnesium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

AML × ivosidenib × 1 year × Clear all

NCT06717958 2025-07-02

PIVOT

Technische Universität Dresden

Phase 2 Recruiting

AML

Data powered by HemOnc (CC BY 4.0) Colophon ⚡